Comparing the Effectiveness and Safety of All Five Botulinum Neurotoxin Type A Products for Treating Frown Lines A Multicenter Randomized Trial
Led by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Updated on 2026-08-14
325
Participants Needed
3
Research Sites
2 weeks
Total Duration
AI-Summary
What This Trial Is About
This trial investigates the effectiveness and safety of all commercially available Botulinum Neurotoxin Type A BoNT-A products for treating moderate to severe glabellar rhytides, commonly known as frown lines, in women aged 18 years or older. The study is a multicenter, triple-blind, randomized controlled trial designed to compare these treatments to identify which offers the longest lasting effect and the best safety profile.
Participants receive injections of one of the five FDA-approved BoNT-A products at specified doses into facial muscles responsible for frown lines. They are randomly assigned to different study groups, each receiving a distinct BoNT-A formulation. The study collects data over 16 weeks with weekly self-taken photographs sent securely for analysis, and follow-up questionnaires to assess satisfaction, quality of life, and symptom changes.
During the study, participants will be monitored through clinical assessments and digital communication to evaluate the duration of treatment efficacy and safety. The primary outcome is the length of clinical effectiveness from baseline to week 16. Secondary outcomes include adverse event incidence, quality of life, social functioning, satisfaction, and symptoms such as depression and anxiety. The study uses advanced statistical analyses to compare treatments and ensure comprehensive safety monitoring throughout the trial period.
CONDITIONS
Brief Title
Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides
Research Team
S
Serge A. Steenen, MD DMD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lead Sponsor
Universitair Medical Centrum Groningen
Collaborating Sponsor
Who Can Participate
Age: 18Years +
FEMALE
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
Women aged 18 years or older with moderate to severe glabellar lines
Willing to provide written informed consent
American Society of Anesthesiologists Physical Status Classification 1 or 2
Negative pregnancy test
You will not qualify if you...
American Society of Anesthesiologists Physical Status Classification 3 or higher
History of allergic reactions to botulinum toxin or its components
Infection at the injection site
Previous treatment with botulinum toxin at any time
Pregnant or breastfeeding women
Neuromuscular disorders or conditions interfering with study assessments
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 16 weeks
Participants receive injections of one of the five Botulinum Neurotoxin Type A products to treat their frown lines.
Weekly photo submissions and periodic clinical assessments
Follow-up
Duration - Up to 30 weeks from baseline
Participants complete questionnaires and attend follow-up visits to assess treatment effects, safety, and satisfaction.
Periodic visits and assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Similar Trials
Evaluating Safety and Effectiveness of Thermage FLX Radiofrequency for Improving Skin Lines, Wrinkles, and Laxity on Neck, Abdomen, Upper Arms, and Face
Evaluation of the AVAVA 1550nm Non-Ablative Fractional Laser Device for Treating Various Dermatologic Conditions with Patient Feedback Collection
Study Evaluating Safety and Effectiveness of INNEA and INNEA AQUA Devices for Treating Wrinkles on Cheeks and Dcolletage in Women Aged 35 to 65
Comparing the Effectiveness and Safety of All Five Botulinum Neurotoxin Type A Products for Treating Frown Lines A Multicenter Randomized Trial
Evaluation of Safety and Bio-revitalizing Effects of Volumizing Filler Based on Hyaluronic Acid and Recombinant Collagen for Facial Wrinkles and Scars
Evaluating the Safety and Effectiveness of the Cytrellis Micro-Coring Device for Treating Moderate to Severe Facial Wrinkles in Adults Aged 40 to 70
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
PrabotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines in Adult Patients With Skin of Color: Post Hoc Analyses of the US Phase III Clinical Study Data.
The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
Z Paul Lorenc, Jeffrey M Adelglass, Rui L Avelar...
DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2).
Complications of facial cosmetic botulinum toxin A injection: analysis of the UK Medicines & Healthcare Products Regulatory Agency registry and literature review.
David Zargaran, Florence E Zoller, Alexander Zargaran...